- This event has passed.
Bipolar Disorder and Co-Occurring Substance Use Disorders
October 18, 2016 @ 12:00 pm - 1:30 pmFree – $15
ABOUT THE PROGRAM
Substance use disorders can be prevalent among individuals who have bipolar disorder. We will discuss clinical presentation and implications for treatment of substance use disorders when co-occurring with bipolar disorder.
1.5 CEUs offered for LPC, LMFT, LCSW, and Clinical Psychologist.
REGISTRATION IS REQUIRED FOR ALL ATTENDEES PRIOR TO THE EVENT. Check in will begin 15 minutes prior to the program beginning. Due to video filming, late attendees will be asked to view the presentation in the Green Room.
In collaboration with DBSA Greater Houston
ABOUT THE SPEAKER
Dr. Sudhakar Selvaraj is an Assistant Professor at the department of Psychiatry and Behavioral Sciences at UT health science center Houston. He is also the Director of UT Health student counselling center, Houston. He qualified in medicine in India and completed clinical psychiatry residency training at Oxford and at Maudsley Hospital and Institute of Psychiatry, London, United Kingdom. He studied the role of serotonin transporters in major depressive disorders for his PhD under the supervision of Professor P.J. Cowen at the department of psychiatry, University of Oxford, UK.
He has broad experience in clinical psychiatry, with specific interest in treating and managing patient with mood disorders such as major depression, bipolar disorder, and anxiety disorders. He has developed expertise in managing ADHD and obsessive-compulsive disorder and in addition, he has substantial experience in managing treatment resistant schizophrenia and early psychosis symptoms. He sees patients at UT Center for Excellence on Mood Disorders and also provide psychiatric care at UTHealth student counseling center.
His research has primarily focused on understanding the neurobiological mechanisms underlying the mood and psychotic disorders. He has specific training and expertise in brain imaging techniques, both structural and functional Magnetic Resonance Imaging/Spectroscopy and Positron Emission Tomography (PET) imaging and its applications in neuropsychiatric disorders. His initial research work was focused on elucidating the role of serotonin transporters (SERT) in major depressive disorder. In a series of studies using Positron Emission Tomography (PET) in conjunction with [11C]DASB, a highly selective 5-HTT radioligand, his team found that abnormalities in SERT availability represent a state abnormality in patients with major depression, which resolves with clinical recovery. These are the first studies in the world investigating SERT in different stages of depression, i.e acute and recovered depression. In another [11C]DASB study, he showed that brain SERT binding in recreational ex-users of 3,4-methylenedioxy-methamphetamine (MDMA), is similar to health control subjects. This finding is of high public health importance as it indicated that neurotoxic effect of acute MDMA use on SERT normalized when MDMA use is discontinued.
His team showed the feasibility of measuring brain serotonin activity using multimodal functional MRI and PET and he demonstrated the direct effect of commonly prescribed antidepressant citalopram on in-vivo 5-HT and on emotion regulation. These studies attempt to unravel the antidepressant treatment mechanisms which could have a major impact in the pathophysiology of mood disorder. He is currently investigating the role of neuroinflammation and oxidative stress in the development of psychiatry illnesses such as mood and psychotic disorders. His team has recently shown that a protein called TSPO or translocator protein (a marker of microglial activation and neuroinflammation) is elevated both in young people at risk of developing psychosis and in patients with schizophrenia. This is the first study investigating brain immune activation in young people with high risk of psychosis. This study is published in American Journal of Psychiatry.
His research has been published in a number of highly cited journals, including American Journal of Psychiatry, Molecular Psychiatry, Biological Psychiatry, Neuropsychopharmacology, British Journal of Psychiatry, Journal of Neuroscience, Psychological Medicine, Bipolar disorder, Neuroscience and Biobehavioral Reviews etc. He has been a recipient of a number of awards and honors, including the National Institute on Drug Abuse (NIDA) travel award, International Society of CNS trial and methodology New Investigator award, American society of psychopharmacology (ASCP) Fellowship Award, American College of Neuropsychopharmacology travel award (ACNP); 2008 Neuroreceptor Mapping Conference travel award; European College of Neuropsychopharmacology (ECNP) Young Scientist Fellowship Award and ECNP Best Research poster award; British Association of Psychopharmacology post-doctoral Bursary Award; ECNP Young Investigator Award; Patricia-Knapp travel award from St Catherine’s College, Oxford; Guarantors of Brain Travel Grant; and the Dennis Hill Prize, King’s College London. His past research was supported by Medical Research Council (UK) core grants and Academy of medical sciences clinical lecturer (UK) start up grant